Dosing of the first patient has started in a Phase 1b\/2a clinical trial of Telomelysin\u00ae injection targeting lower rectal cancer and anal cancer. The trial evaluates the efficacy and safety of Telomelysin\u00ae injection combined with preoperative chemoradiotherapy for local tumors. The aim is to contribute to a clinical approach that avoids stoma creation. Impact on the fiscal year ending December 2026 is expected to be minimal (unspecified).<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4588","jir_company_name":"Oncolys BioPharma Inc.","jir_importance":"\u2605\u2605\u2605\u2606\u2606","jir_publication_date":"2026-10-30","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/10\/4588-20261030-01.pdf","jir_short_summary":"Dosing of the first patient has started in a Phase 1b\/2a clinical trial of Telomelysin\u00ae injection targeting lower rectal cancer and anal cancer. The trial evaluates the efficacy and safety of Telomelysin\u00ae injection combined with preoperative chemoradiotherapy for local tumors. The aim is to contribute to a clinical approach that avoids stoma creation. Impact on the fiscal year ending December 2026 is expected to be minimal (unspecified).","jir_summary":"### Business and R&D Latest Developments\nOncolys BioPharma Inc. has initiated a Phase 1b\/2a clinical trial aiming for a new indication of the oncolytic virus Telomelysin\u00ae injection (OBP-301). This trial targets lower rectal cancer and anal cancer and will evaluate the efficacy and safety of Telomelysin\u00ae injection in combination with preoperative chemoradiotherapy for local tumors. The objective is to potentially contribute to a care pathway that avoids stoma creation.\n\n### Financial Impact and Outlook\nThe impact on the fiscal results for the fiscal year ending December 2026 is considered minimal; however, specific amounts and timing are unspecified. Progress in the clinical trial is an important step toward broader therapeutic application and may affect medium- to long-term business growth.","jir_financial_highlights":"Net Sales: Unknown (Unknown)\nFiscal Period: Fiscal year ending December 2026 (Unknown)","jir_category":"","jir_hashtags":"#OncolysBioPharma, #ClinicalTrial, #OncologyTreatment","jir_key_figures":"Fiscal year ending December 2026: Unknown\nClinical trial start: First patient dosed\nRelated therapy name: Telomelysin\u00ae injection (OBP-301)","jir_meta_title":"Oncolys BioPharma Inc. \u2014 Dosing Initiated in Clinical Trial for New Indication\uff5cOctober 2026","jir_meta_description":"Oncolys BioPharma Inc. announced the first patient dosing in a Phase 1b\/2a clinical trial of OBP-301 aiming for a new indication. This article explains the efficacy and safety evaluation for lower rectal and anal cancer and the outlook toward avoiding stoma creation.","jir_og_title":"Oncolys BioPharma Inc. \u2014 Initiation of Clinical Trial for New Indication","jir_og_description":"Announcement of first patient dosing in the Phase 1b\/2a trial of OBP-301. The effort aims to realize a care pathway that avoids stoma creation, with stated minimal impact on financial results.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":56785,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"executive_change","footnotes":""},"sector":[],"importance":[],"class_list":["post-138901","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n